bayer Stock Reacts to Potential Glyphosate Lawsuit strategy
Table of Contents
Shares stabilize amidst speculation of “Texas two-Step” insolvency maneuver for Monsanto-related glyphosate claims.
Bayer’s stock demonstrated resilience on Friday, recovering from recent volatility. Shares of the Leverkusen-based company increased by as much as 3.3%, reaching a level of €23.62, coinciding with the 200-day moving average. This follows a period of significant price swings, with the stock peaking near €27 on tuesday before plummeting to around €22 the following day.
“Texas Two-Step” Strategy under Consideration
the renewed investor confidence appears linked to reports concerning Bayer’s potential strategy for managing the extensive glyphosate-related lawsuits stemming from its acquisition of Monsanto. According to a report in the Wall Street Journal
, Bayer is exploring a complex legal maneuver known as the “Texas Two-Step.” This strategy involves creating a subsidiary to absorb the monsanto liabilities and then declaring bankruptcy for that subsidiary, perhaps shielding Bayer from direct duty for the numerous damage claims [[3]].
The “Texas Two-Step” is a controversial legal strategy that has faced scrutiny and challenges in other contexts.
Though, legal experts caution that significant hurdles remain before this strategy could be successfully implemented. The legal landscape surrounding corporate bankruptcy and liability is complex, and Bayer would likely face considerable opposition from plaintiffs seeking compensation for alleged harm caused by glyphosate exposure.
Glyphosate Litigation: An Ongoing Overhang
The shadow of glyphosate litigation has loomed large over Bayer since its $63 billion acquisition of Monsanto in 2018 [[1]]. Tens of thousands of lawsuits allege that exposure to roundup, Monsanto’s glyphosate-based herbicide, caused cancer. While Bayer has maintained that glyphosate is safe when used as directed,juries have often sided with plaintiffs,awarding significant damages [[2]].
One expert noted that speculation about Bayer potentially using such a legal strategy has circulated for years, with Bloomberg News reporting on the possibility as far back as spring 2024. while Bayer has declined to comment directly on the “Texas Two-Step” reports,the expert suggests that the glyphosate issue continues to be a source of volatility for the company’s stock.
Supreme Court Decision Looms
JPMorgan analyst Richard Vosser highlighted the importance of the U.S. Supreme Court’s potential decision on the Durnell case regarding glyphosate. Bayer submitted the case for consideration in early April, and the question of whether the court will hear it remains open. A decision is anticipated before the end of the current session, which typically concludes in late June or early july. The Supreme court’s decision could significantly impact the future trajectory of glyphosate litigation and Bayer’s financial exposure.
The Future of Glyphosate
Bayer has already taken steps to mitigate future litigation risk, including halting sales of glyphosate-based products to U.S. private customers. However, the existing legal challenges continue to weigh on the company. The outcome of the “texas Two-Step” consideration, coupled with the Supreme Court’s decision on the Durnell case, will be critical in determining Bayer’s long-term strategy for managing the glyphosate liability and restoring investor confidence.
